Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSamita Garg
About this trial
A pilot study to evaluate and compare glucose metrics using a real-time continuous glucose monitor (FreeStyle Libre 3 sensor) between patients with diabetes and gastroparesis and those with diabetes without gastroparesis.
Eligibility criteria
Qualifiers
Over the age of 18 years.
Hemoglobin A1c ≤11% within the last 6 months.
Patients with diagnosis of type 1 Diabetes or type 2 Diabetes for at least one year.
Normal thyroid-stimulating hormone (TSH) within the last year.
Disqualifiers
Hemoglobin A1c of >11% at enrollment.
Advanced chronic kidney disease (serum creatinine of >2 mg/dL or estimated glomerular filtration rate (eGFR) <30mL/min/1.73m² using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula).
Advanced and significant cardiovascular disease or unstable angina.
Advanced liver disease that may affect glucose profiles.
Trial design
Treatments tested in this trial
- FreeStyle Libre 3 continuous glucose monitoring sensor
- Nutritional drink
Treatment groups
50 Participants
are divided into 2 treatment groupsLocations
1Cleveland Clinic Foundation44195, ClevelandOhio, United States
Sponsors and collaborators
Samita Garg
Lead sponsor
The Cleveland Clinic
Sponsor institution
Source ClinicalTrials.gov